New lupus drug candidate D-2570 enters Mid-Stage trial
NCT ID NCT07311200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the experimental drug D-2570 can help people with active systemic lupus erythematosus (SLE). About 120 adults with moderate-to-severe lupus will be randomly assigned to receive either D-2570 or a placebo. The main goal is to see if D-2570 improves lupus symptoms and disease activity after 32 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D-2570
- What this could lead to
- If successful, this could lead to a new treatment option for people with active lupus, helping to control the disease and reduce symptoms.
- What could go wrong
- This is an early phase 2 trial with only 120 people. The drug may not work better than placebo, and side effects are still being studied. It is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linfen Central Hospital
RECRUITINGLinfen, Jiangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.